TreatmentTrends: Breast Cancer Q4 2015 (US) is the second in a series of reports examining current trends in the management of advanced/metastatic breast cancer from the perspective of medical oncologists. In this report, a comparison between two waves of research provides an overview of changes in treatment practices in the past six months. TreatmentTrends are syndicated reports that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends reports evaluate perceived product advantages and disadvantages, as well as the sales and messaging efforts of key market players.
Questions Answered in This Report:
- Compare, between consecutive waves of research, the reported use of hormone therapy, chemotherapy, and targeted therapy for advanced/metastatic breast cancer patients. How does prescribing of currently available therapies differ by hormone receptor (HR) and human epidermal growth factor receptor (HER2) status and by line of therapy? How has prescribing changed over the past six months?
- Assess how the importance and performance of various attributes (e.g., efficacy, safety, dosing) differ between products. For example, how important an attribute is improvement in quality of life according to surveyed medical oncologists? How do products available today, such as Roche/Genentech/Chugai’s Herceptin, perform on this attribute? What hidden opportunities are available for drug manufacturers?
- Assess sales representative contact frequency, sales representative performance, and physician message recall between products. How many times, on average, in the past six months has a sales representative visited physicians for the various current therapies? What percentages of physicians were visited in the past month, and what messages were recalled by brand?
- Understand medical oncologists’ perception of late-stage breast cancer therapies, including awareness of and familiarity with products in late-stage development. The report covers approximately 15 products in late-stage development. What are surveyed physicians’ most desired attributes for future advanced/metastatic breast cancer therapies? Has this desire changed since the Q2 Breast Cancer Q4 2015 US report? How do surveyed oncologists rank future breast cancer treatments (including the PI3K inhibitors, the PARP inhibitors, HDAC inhibitors, and vaccines)?
Markets covered: United States.
Primary research: 100 medical oncologists.
Indication coverage: Advanced/metastatic breast cancer.